Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab dose-frequency optimization in advanced or metastatic non-small cell lung cancer
2015-004633-27Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival rate at 6 months after randomization and Progression-free survival rate at 1 year after randomization. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-004633-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004633-27.